![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Resistance analyses of HCV isolates from patients treated with simeprevir in Phase IIB/III studies
|
|
|
Reported by Jules Levin
AASLD 2013 Nov 1-4 Wash DC
Oliver Lenz,1 Bart Fevery,1 Thierry Verbinnen,1 Lotke Tambuyzer,1 Leen Vijgen,1 Monika Peeters,1 Maria Beumont-Mauviel,1 Gaston Picchio,2 Sandra De Meyer1
1Janssen Infectious Diseases BVBA, Beerse, Belgium; 2Janssen Research & Development, LLC, Titusville, NJ, USA
![AASLD1.gif](../images/111013/111013-8/AASLD1.gif)
![AASLD2.gif](../images/111013/111013-8/AASLD2.gif)
![AASLD3.gif](../images/111013/111013-8/AASLD3.gif)
![AASLD4.gif](../images/111013/111013-8/AASLD4.gif)
![AASLD5.gif](../images/111013/111013-8/AASLD5.gif)
![AASLD6.gif](../images/111013/111013-8/AASLD6.gif)
![AASLD7.gif](../images/111013/111013-8/AASLD7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|